Nov 11, 2025 • Benzinga
SOMEWHAT-BEARISH
Neurocrine's Depression Drug Fails Phase 2 Goal But Shows Encouraging Safety Profile - Neurocrine Biosciences ( NASDAQ:NBIX )
On Monday, Neurocrine Biosciences, Inc. ( NASDAQ:NBIX ) said its Phase 2 study of NBI-1070770 in adults with major depressive disorder did not meet the primary endpoint compared to placebo, though it was generally well tolerated.
Nov 11, 2025 • Zacks Commentary
BULLISH
Looking for a Growth Stock? 3 Reasons Why Neurocrine ( NBIX ) is a Solid Choice
Neurocrine (NBIX) possesses solid growth attributes, which could help it handily outperform the market.
Nov 11, 2025 • Benzinga
SOMEWHAT-BULLISH
Zoom To Rally Around 38%? Here Are 10 Top Analyst Forecasts For Tuesday - Bullish ( NYSE:BLSH ) , Appian ( NASDAQ:APPN )
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page. Baird raised RealReal Inc ( NASDAQ:REAL ) price target from $8 to $13.
Nov 10, 2025 • GlobeNewswire
SOMEWHAT-BULLISH
Transition Bio and Voyager Announce Collaboration to Advance Small Molecules Targeting TDP-43 in ALS and Frontotemporal Dementia
CAMBRIDGE, United Kingdom and LEXINGTON, Mass., Nov. 10, 2025 ( GLOBE NEWSWIRE ) -- Transition Bio, a drug discovery company focused on unlocking traditionally "undruggable" targets by leveraging biomolecular condensates, and Voyager Therapeutics ( Nasdaq: VYGR ) , a biotechnology company ...
Nov 10, 2025 • GlobeNewswire
NEUTRAL
Voyager Reports Third Quarter 2025 Financial and Operating Results
- Momentum building around tau: expect VY7523 clinical data and VY1706 clinical entry in ...
Nov 06, 2025 • Zacks Commentary
BULLISH
Earnings Estimates Rising for Neurocrine ( NBIX ) : Will It Gain?
Neurocrine Biosciences (NBIX) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.